# Clinical trial results:
# A Phase 1b/2 Study with Gemcitabine and LY2157299 for Patients with Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2)

## Summary

| | |
|---|---|
| EudraCT number | 2011-000211-64 |
| Trial protocol | ES BE DE IT |
| Global end of trial date | 09 February 2016 |

### Results information

| | |
|---|---|
| Result version number | v1 (current) |
| This version publication date | 05 January 2018 |
| First version publication date | 05 January 2018 |

## Trial information

### Trial identification

| | |
|---|---|
| Sponsor protocol code | H9H-MC-JBAJ |

### Additional study identifiers

| | |
|---|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT01373164 |
| WHO universal trial number (UTN) | - |
| Other trial identifiers | Trial Alias: 13663 |

Notes:

### Sponsors

| | |
|---|---|
| Sponsor organisation name | Eli Lilly and Company |
| Sponsor organisation address | Lilly Corporate Center, Indianapolis, IN, United States, 46285 |
| Public contact | Available Mon Fri 9 AM 5 PM EST, Eli Lilly and Company, 1 877CTLilly, |
| Scientific contact | Available Mon Fri 9 AM 5 PM EST, Eli Lilly and Company, 1 8772854559, |

Notes:

### Paediatric regulatory details

| | |
|---|---|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

| | |
|---|---|
| Analysis stage | Final |
| Date of interim/final analysis | 09 February 2016 |
| Is this the analysis of the primary completion data? | No |

| | |
|---|---|
| Global end of trial reached? | Yes |
| Global end of trial date | 09 February 2016 |
| Was the trial ended prematurely? | No |

Notes:

## General information about the trial

Main objective of the trial:

Phase 1b: To determine the safe and tolerable dose of galunisertib in combination with gemcitabine in patients with solid malignancy

Phase 2a: To compare the overall survival (OS) of patients with Stage II to IV unresectable pancreatic cancer when treated with a combination of galunisertib and gemcitabine with that of gemcitabine plus placebo.

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonization (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy: -

Evidence for comparator: -

| | |
|---|---|
| Actual start date of recruitment | 07 June 2011 |
| Long term follow-up planned | Yes |
| Long term follow-up rationale | Safety, Efficacy |
| Long term follow-up duration | 1 Months |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

## Population of trial subjects

### Subjects enrolled per country

| | |
|---|---|
| Country: Number of subjects enrolled | Belgium: 6 |
| Country: Number of subjects enrolled | United States: 19 |
| Country: Number of subjects enrolled | Italy: 33 |
| Country: Number of subjects enrolled | France: 30 |
| Country: Number of subjects enrolled | Germany: 36 |
| Country: Number of subjects enrolled | Spain: 45 |
| Worldwide total number of subjects | 169 |
| EEA total number of subjects | 150 |

Notes:

### Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 | 0 |

| wk | |
|---|---|
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 65 |
| From 65 to 84 years | 104 |
| 85 years and over | 0 |

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

Completers included participants who died from any cause and participants who were alive and on study (either on study treatment or in long term follow-up) at study conclusion.

### Period 1

| | |
|---|---|
| Period 1 title | Overall Study |
| Is this the baseline period? | No |
| Allocation method | Non-randomised - controlled |
| Blinding used | Not blinded |

### Arms

| | |
|---|---|
| Are arms mutually exclusive? | Yes |
| **Arm title** | Phase 1b: 80 mg (milligrams) Galunisertib + Gemcitabine |

Arm description:

Cohort 1: 40 mg Galunisertib was administered orally twice daily (BID) for 14 days followed by 14 days of rest (28 day cycle).

Gemcitabine at a dose of 1000 mg/m^2 (milligrams per square meter) was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Gemcitabine |
| Investigational medicinal product code | |
| Other name | Gemzar |
| Pharmaceutical forms | Powder for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

| | |
|---|---|
| Investigational medicinal product name | Galunisertib |
| Investigational medicinal product code | LY2157299 |
| Other name | |
| Pharmaceutical forms | Coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

40 mg Galunisertib was administered orally twice daily (BID) for 14 days followed by 14 days of rest (28 day cycle).

| | |
|---|---|
| **Arm title** | Phase 1b: 160 mg Galunisertib + Gemcitabine |

Arm description:

Cohort 2: 80 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

| | |
|---|---|
| Arm type | Experimental |

| | |
|---|---|
| Investigational medicinal product name | Galunisertib |
| Investigational medicinal product code | LY2157299 |
| Other name | |
| Pharmaceutical forms | Coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

80 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

| | |
|---|---|
| Investigational medicinal product name | Gemcitabine |
| Investigational medicinal product code | |
| Other name | Gemzar |
| Pharmaceutical forms | Powder for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

| | |
|---|---|
| **Arm title** | Phase 1b: 300 mg Galunisertib + Gemcitabine |

Arm description:

Cohort 3: 150 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Gemcitabine |
| Investigational medicinal product code | |
| Other name | Gemzar |
| Pharmaceutical forms | Powder for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

| | |
|---|---|
| Investigational medicinal product name | Galunisertib |
| Investigational medicinal product code | LY2157299 |
| Other name | |
| Pharmaceutical forms | Coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

150 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

| | |
|---|---|
| **Arm title** | Phase 2: 300 mg Galunisertib + Gemcitabine |

Arm description:

Galunisertib recommended dose (300 mg) determined from phase 1, administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Gemcitabine |
| Investigational medicinal product code | |
| Other name | Gemzar |
| Pharmaceutical forms | Powder for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks

followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

| | |
|---|---|
| Investigational medicinal product name | Galunisertib |
| Investigational medicinal product code | LY2157299 |
| Other name | |
| Pharmaceutical forms | Coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

150 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

| | |
|---|---|
| **Arm title** | Phase 2: Placebo + Gemcitabine |

Arm description:

Placebo administered orally twice daily for 14 days followed 14 days of rest (28 day cycle).

Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

| | |
|---|---|
| Arm type | Active comparator |
| Investigational medicinal product name | Gemcitabine |
| Investigational medicinal product code | |
| Other name | Gemzar |
| Pharmaceutical forms | Powder for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

| | |
|---|---|
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Placebo administered orally twice daily for 14 days followed 14 days of rest (28 day cycle).

| **Number of subjects in period 1** | Phase 1b: 80 mg (milligrams) Galunisertib + Gemcitabine | Phase 1b: 160 mg Galunisertib + Gemcitabine | Phase 1b: 300 mg Galunisertib + Gemcitabine |
|---|---|---|---|
| Started | 5 | 4 | 5 |
| Received at least one dose | 5 | 4 | 5 |
| Completed | 5 | 3 | 4 |
| Not completed | 0 | 1 | 1 |
| Consent withdrawn by subject | - | 1 | - |
| Lost to follow-up | - | - | 1 |

| **Number of subjects in period 1** | Phase 2: 300 mg Galunisertib + Gemcitabine | Phase 2: Placebo + Gemcitabine |
|---|---|---|
| Started | 104 | 52 |
| Received at least one dose | 103 | 52 |
| Completed | 92 | 50 |
| Not completed | 12 | 2 |

| | | |
|---|---|---|
| Consent withdrawn by subject | 10 | 2 |
| Lost to follow-up | 2 | - |

## Period 2

| | |
|---|---|
| Period 2 title | Received at Least One Dose |
| Is this the baseline period? | Yes[1] |
| Allocation method | Non-randomised - controlled |
| Blinding used | Not blinded |

## Arms

| | |
|---|---|
| Are arms mutually exclusive? | No |
| **Arm title** | Phase 1b: 80 mg Galunisertib + Gemcitabine |

Arm description:

Cohort 1: 40 mg Galunisertib was administered orally twice daily (BID) for 14 days followed by 14 days of rest (28 day cycle).
Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Gemcitabine |
| Investigational medicinal product code | |
| Other name | Gemzar |
| Pharmaceutical forms | Powder for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

| | |
|---|---|
| Investigational medicinal product name | Galunisertib |
| Investigational medicinal product code | LY2157299 |
| Other name | |
| Pharmaceutical forms | Coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

40 mg Galunisertib was administered orally twice daily (BID) for 14 days followed by 14 days of rest (28 day cycle).

| | |
|---|---|
| **Arm title** | Phase 1b: 160 mg Galunisertib + Gemcitabine |

Arm description:

Cohort 2: 80 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).
Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Galunisertib |
| Investigational medicinal product code | LY2157299 |
| Other name | |
| Pharmaceutical forms | Coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

80 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

| | |
|---|---|
| Investigational medicinal product name | Gemcitabine |
| Investigational medicinal product code | |
| Other name | Gemzar |
| Pharmaceutical forms | Powder for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

| | |
|---|---|
| **Arm title** | Phase 1b: 300 mg Galunisertib + Gemcitabine |

Arm description:

Cohort 3: 150 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).
Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Galunisertib |
| Investigational medicinal product code | LY2157299 |
| Other name | |
| Pharmaceutical forms | Coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

150 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

| | |
|---|---|
| Investigational medicinal product name | Gemcitabine |
| Investigational medicinal product code | |
| Other name | Gemzar |
| Pharmaceutical forms | Powder for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

| | |
|---|---|
| **Arm title** | Phase 2: 300 mg Galunisertib + Gemcitabine |

Arm description:

Galunisertib recommended dose (300 mg) determined from phase 1, administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).
Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Gemcitabine |
| Investigational medicinal product code | |
| Other name | Gemzar |
| Pharmaceutical forms | Powder for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

| | |
|---|---|
| Investigational medicinal product name | Galunisertib |
| Investigational medicinal product code | LY2157299 |
| Other name | |
| Pharmaceutical forms | Coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

150 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

| **Arm title** | Phase 2: Placebo + Gemcitabine |
|---|---|

Arm description:

Placebo administered orally twice daily for 14 days followed 14 days of rest (28 day cycle). Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

| Arm type | Experimental |
|---|---|
| Investigational medicinal product name | Gemcitabine |
| Investigational medicinal product code | |
| Other name | Gemzar |
| Pharmaceutical forms | Powder for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

| Investigational medicinal product name | Placebo |
|---|---|
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Placebo administered orally twice daily for 14 days followed 14 days of rest (28 day cycle).

Notes:

[1] - Period 1 is not the baseline period. It is expected that period 1 will be the baseline period.

Justification: The baseline characteristics are calculated for participants who received at least one dose of study drug as per SAP.

| **Number of subjects in period 2** | Phase 1b: 80 mg Galunisertib + Gemcitabine | Phase 1b: 160 mg Galunisertib + Gemcitabine | Phase 1b: 300 mg Galunisertib + Gemcitabine |
|---|---|---|---|
| Started | 5 | 4 | 5 |
| Completed | 5 | 3 | 4 |
| Not completed | 0 | 1 | 1 |
| Consent withdrawn by subject | - | 1 | - |
| Lost to follow-up | - | - | 1 |

| **Number of subjects in period 2** | Phase 2: 300 mg Galunisertib + Gemcitabine | Phase 2: Placebo + Gemcitabine |
|---|---|---|
| Started | 103 | 52 |
| Completed | 92 | 50 |
| Not completed | 11 | 2 |
| Consent withdrawn by subject | 9 | 2 |
| Lost to follow-up | 2 | - |

## Baseline characteristics

| Reporting groups | |
|---|---|
| Reporting group title | Phase 1b: 80 mg Galunisertib + Gemcitabine |
| Reporting group description: | |
| Cohort 1: 40 mg Galunisertib was administered orally twice daily (BID) for 14 days followed by 14 days of rest (28 day cycle).<br>Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks. | |
| Reporting group title | Phase 1b: 160 mg Galunisertib + Gemcitabine |
| Reporting group description: | |
| Cohort 2: 80 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).<br>Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks. | |
| Reporting group title | Phase 1b: 300 mg Galunisertib + Gemcitabine |
| Reporting group description: | |
| Cohort 3: 150 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).<br>Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks. | |
| Reporting group title | Phase 2: 300 mg Galunisertib + Gemcitabine |
| Reporting group description: | |
| Galunisertib recommended dose (300 mg) determined from phase 1, administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).<br>Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks. | |
| Reporting group title | Phase 2: Placebo + Gemcitabine |
| Reporting group description: | |
| Placebo administered orally twice daily for 14 days followed 14 days of rest (28 day cycle).<br>Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks. | |

| Reporting group values | Phase 1b: 80 mg Galunisertib + Gemcitabine | Phase 1b: 160 mg Galunisertib + Gemcitabine | Phase 1b: 300 mg Galunisertib + Gemcitabine |
|---|---|---|---|
| Number of subjects | 5 | 4 | 5 |
| Age categorical<br>Units: Subjects | | | |
| In utero<br>Preterm newborn infants (gestational age < 37 wks)<br>Newborns (0-27 days)<br>Infants and toddlers (28 days-23 months)<br>Children (2-11 years)<br>Adolescents (12-17 years)<br>Adults (18-64 years)<br>From 65-84 years<br>85 years and over | | | |
| Age Continuous<br>Units: Years | | | |
| arithmetic mean | 63.2 | 63.8 | 56.6 |
| standard deviation | ± 12.9 | ± 9.0 | ± 9.2 |

| | | | |
|---|---|---|---|
| Gender categorical<br>Units: Subjects | | | |
| Female | 0 | 3 | 3 |
| Male | 5 | 1 | 2 |
| Ethnicity (NIH/OMB)<br>Units: Subjects | | | |
| Hispanic or Latino | 0 | 0 | 1 |
| Not Hispanic or Latino | 5 | 4 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)<br>Units: Subjects | | | |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 0 |
| White | 3 | 4 | 5 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment<br>Units: Subjects | | | |
| Belgium | 0 | 0 | 0 |
| United States | 5 | 2 | 1 |
| Italy | 0 | 0 | 0 |
| France | 0 | 0 | 0 |
| Germany | 0 | 0 | 0 |
| Spain | 0 | 2 | 4 |

| **Reporting group values** | Phase 2: 300 mg Galunisertib + Gemcitabine | Phase 2: Placebo + Gemcitabine | Total |
|---|---|---|---|
| Number of subjects | 103 | 52 | 169 |
| Age categorical<br>Units: Subjects | | | |
| In utero | | | |
| Preterm newborn infants (gestational age < 37 wks) | | | |
| Newborns (0-27 days) | | | |
| Infants and toddlers (28 days-23 months) | | | |
| Children (2-11 years) | | | |
| Adolescents (12-17 years) | | | |
| Adults (18-64 years) | | | |
| From 65-84 years | | | |
| 85 years and over | | | |
| Age Continuous<br>Units: Years | | | |
| arithmetic mean | 67.3 | 66.3 | |
| standard deviation | ± 8.2 | ± 8.9 | - |
| Gender categorical<br>Units: Subjects | | | |
| Female | 46 | 24 | 76 |
| Male | 57 | 28 | 93 |

| Ethnicity (NIH/OMB)<br>Units: Subjects | | | |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 |
| Not Hispanic or Latino | 37 | 18 | 68 |
| Unknown or Not Reported | 66 | 34 | 100 |
| Race (NIH/OMB)<br>Units: Subjects | | | |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 2 |
| White | 95 | 50 | 157 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 8 | 2 | 10 |
| Region of Enrollment<br>Units: Subjects | | | |
| Belgium | 4 | 2 | 6 |
| United States | 7 | 4 | 19 |
| Italy | 23 | 10 | 33 |
| France | 21 | 9 | 30 |
| Germany | 22 | 14 | 36 |
| Spain | 26 | 13 | 45 |

## End points

### End points reporting groups

| Reporting group title | Phase 1b: 80 mg (milligrams) Galunisertib + Gemcitabine |
|---|---|

Reporting group description:

Cohort 1: 40 mg Galunisertib was administered orally twice daily (BID) for 14 days followed by 14 days of rest (28 day cycle).

Gemcitabine at a dose of 1000 mg/m^2 (milligrams per square meter) was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

| Reporting group title | Phase 1b: 160 mg Galunisertib + Gemcitabine |
|---|---|

Reporting group description:

Cohort 2: 80 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

| Reporting group title | Phase 1b: 300 mg Galunisertib + Gemcitabine |
|---|---|

Reporting group description:

Cohort 3: 150 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

| Reporting group title | Phase 2: 300 mg Galunisertib + Gemcitabine |
|---|---|

Reporting group description:

Galunisertib recommended dose (300 mg) determined from phase 1, administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).

Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

| Reporting group title | Phase 2: Placebo + Gemcitabine |
|---|---|

Reporting group description:

Placebo administered orally twice daily for 14 days followed 14 days of rest (28 day cycle).

Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

| Reporting group title | Phase 1b: 80 mg Galunisertib + Gemcitabine |
|---|---|

Reporting group description:

Cohort 1: 40 mg Galunisertib was administered orally twice daily (BID) for 14 days followed by 14 days of rest (28 day cycle).
Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

| Reporting group title | Phase 1b: 160 mg Galunisertib + Gemcitabine |
|---|---|

Reporting group description:

Cohort 2: 80 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).
Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

| Reporting group title | Phase 1b: 300 mg Galunisertib + Gemcitabine |
|---|---|

Reporting group description:

Cohort 3: 150 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).
Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

| Reporting group title | Phase 2: 300 mg Galunisertib + Gemcitabine |
|---|---|

Reporting group description:

Galunisertib recommended dose (300 mg) determined from phase 1, administered orally twice daily for

14 days followed by 14 days of rest (28 day cycle).
Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

| Reporting group title | Phase 2: Placebo + Gemcitabine |
|---|---|

Reporting group description:

Placebo administered orally twice daily for 14 days followed 14 days of rest (28 day cycle).
Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

| Subject analysis set title | Phase 1b Participants |
|---|---|
| Subject analysis set type | Intention-to-treat |

Subject analysis set description:

Participants received galunisertib at a starting dose of 80 mg/day in combination with gemcitabine. Dose escalation proceeded in cohorts of between 3 to 6 evaluable participants until ≥2 participants experienced a dose limiting toxicity (DLT) or an galunisertib dose level of 300 mg/day was reached.

## Primary: Phase 1b: Recommended Phase 2 dose

| End point title | Phase 1b: Recommended Phase 2 dose[1] |
|---|---|

End point description:

The recommended Phase 2 dose was the highest dose where less than 1/3 of participants experienced dose limiting toxicities (DLTs). The recommended dose was determined based on a review of overall toxicity, dose reductions, omissions, and pharmacokinetic information from Phase 1b.
Analysis Population Description: All participants who received at least one dose of study drug.

| End point type | Primary |
|---|---|

End point timeframe:

Time of first phase 1b dose until time of last phase 1b dose (up to1 year)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistics are being reported for all randomized participants per the protocol or Statistical Analysis Plan.

| End point values | Phase 1b Participants | | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 14 | | | |
| Units: milligrams (mg) | | | | |
| number (not applicable) | 300 | | | |

### Statistical analyses

No statistical analyses for this end point

## Primary: Phase 2: Overall Survival (OS)

| End point title | Phase 2: Overall Survival (OS) |
|---|---|

End point description:

Overall survival is defined as the time from the date of randomization to the date of death from any cause. For each participant who is not known to have died as of the data-inclusion cut-off date for a particular analysis, overall survival duration was censored for that analysis at the date of last prior contact.
Analysis Population Description: All randomized participants who received at least one dose of study drug and had baseline & at least one post baseline observation. Number of participants censored were Galunisertib + Gemcitabine = 20 and Placebo + Gemcitabine = 4.

| End point type | Primary |
|---|---|

End point timeframe:

Baseline to date of death from any cause (up to 2 years)

| **End point values** | Phase 2: 300 mg Galunisertib + Gemcitabine | Phase 2: Placebo + Gemcitabine | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 104 | 52 | | |
| Units: Months | | | | |
| median (confidence interval 95%) | 8.9 (7.3 to 11.1) | 7.1 (5.8 to 9.0) | | |

**Statistical analyses**

| **Statistical analysis title** | STATISTICAL_ANALYSIS_TITLE |
|---|---|
| Comparison groups | Phase 2: 300 mg Galunisertib + Gemcitabine v Phase 2: Placebo + Gemcitabine |
| Number of subjects included in analysis | 156 |
| Analysis specification | Pre-specified |
| Analysis type | superiority[2] |
| Method | Bayesian Analysis |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.794 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.59 |
| upper limit | 1.085 |

Notes:

[2] - The planned primary analysis for this study utilized a Bayesian exponential-likelihood model, incorporating historical overall survival (OS) data from 2 studies (Oettle et al. 2005; Saif et al. 2009). The primary analysis was performed using strong borrowing from the historical data. The model was estimated to borrow approximately 37 events from the historical studies.

**Secondary: Phase 1b: Pharmacokinetics: Area Under the Concentration-Time Curve at steady state From Time Zero to 24 Hours (AUC[0-24], ss) and Time Zero to Infinity (AUC[0-∞], ss)**

| End point title | Phase 1b: Pharmacokinetics: Area Under the Concentration-Time Curve at steady state From Time Zero to 24 Hours (AUC[0-24], ss) and Time Zero to Infinity (AUC[0-∞], ss) |
|---|---|

End point description:

For Arm: Phase 1b: 160 mg Galunisertib + Gemcitabine, the geometric mean and geometric coefficient of variation was not analyzed.
Analysis Population Description: Phase 1b: All participants who received at least one dose of study drug and had evaluable PK data.

| End point type | Secondary |
|---|---|

End point timeframe:

Cycle 1 Days 14 (predose; 0.5, 2, 3, and 6 hours post dose), Days 15 and 16 (predose )

| End point values | Phase 1b: 80 mg (milligrams) Galunisertib + Gemcitabine | Phase 1b: 300 mg Galunisertib + Gemcitabine | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 3 | 3 | | |
| Units: nanogram*hour per milliliter (ng*h/mL) | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| AUC(0-24) | 2530 (± 116) | 9090 (± 27) | | |
| AUC(0-∞) | 2740 (± 117) | 10600 (± 10) | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 1b: Pharmacokinetics: maximum plasma drug concentration at steady state (Cmax,ss)

| End point title | Phase 1b: Pharmacokinetics: maximum plasma drug concentration at steady state (Cmax,ss) |
|---|---|

End point description:

For arm 160 mg Galunisertib + Gemcitabine, the geometric mean and geometric coefficient of variation were not analyzed.
Analysis Population Description: Phase 1b: All participants who received at least one dose of study drug and had evaluable PK data.

| End point type | Secondary |
|---|---|

End point timeframe:

Cycle 1: Days 14 (predose; 0.5, 2, 3, and 6 hours post dose), Days 15 and 16 (predose )

| End point values | Phase 1b: 80 mg (milligrams) Galunisertib + Gemcitabine | Phase 1b: 300 mg Galunisertib + Gemcitabine | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 3 | 3 | | |
| Units: nanogram per milliliter (ng/mL) | | | | |
| geometric mean (geometric coefficient of variation) | 385 (± 101) | 1050 (± 39) | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 1b: Number of participants with tumor response

| End point title | Phase 1b: Number of participants with tumor response |
|---|---|

End point description:

Response was defined using RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1. Complete Response (CR) was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 millimeter (mm) and normalization of tumor marker level of non-target lesions; Partial Response (PR) was defined as having at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD) was defined as having at least 20% increase in sum of longest diameter of target lesions and minimum 5 mm increase above nadir; Stable Disease (SD) was defined as small changes that did not meet above criteria.
Analysis Population Description: Phase 1b: All participants who received at least one dose of study drug.

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline to end of Phase 1b (up to 1 year)

| End point values | Phase 1b: 80 mg (milligrams) Galunisertib + Gemcitabine | Phase 1b: 160 mg Galunisertib + Gemcitabine | Phase 1b: 300 mg Galunisertib + Gemcitabine | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 5 | 4 | 5 | |
| Units: Participants | | | | |
| number (not applicable) | | | | |
| Progressive Disease (PD) | 3 | 1 | 2 | |
| Stable Disease (SD) | 1 | 2 | 2 | |
| Partial Response (PR) | 0 | 1 | 0 | |
| Non-Complete Response/Non-Progressive Disease (NC) | 0 | 0 | 1 | |
| Not Assessed (NA) | 1 | 0 | 0 | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2: Progression Free Survival (PFS)

| End point title | Phase 2: Progression Free Survival (PFS) |
|---|---|

End point description:

PFS is defined as the date of randomization to the first date of progression of disease or of death from any cause. For each participant who is not known to have died or to have had a progression of disease as of the data-inclusion cut-off date for a particular analysis, PFS will be censored at the date of last prior contact. PFS will be calculated and analyzed twice: (1) including clinical progressions of disease not based on lesion measurements, and (2) excluding clinical progressions. Progression Disease (PD) was defined as having at least a 25% increase in the sum of the longest diameter of target lesions.
Analysis Population Description: All randomized participants who received at least one dose of study drug and had baseline & at least one post baseline observation. Number of participants censored were Galunisertib + Gemcitabine = 21 and Placebo + Gemcitabine = 11.

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline to first date of progressive disease or death due to any cause (up to 2 years)

| End point values | Phase 2: 300 mg Galunisertib + Gemcitabine | Phase 2: Placebo + Gemcitabine | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 104 | 52 | | |
| Units: Months | | | | |
| median (confidence interval 95%) | 4.11 (2.66 to 5.42) | 2.86 (1.94 to 3.75) | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2: Percentage change from baseline in tumor size (CTS)

| End point title | Phase 2: Percentage change from baseline in tumor size (CTS) |
|---|---|

End point description:

Change in tumor size is defined as the maximum percent change from baseline in the sum of target lesions. Change was assessed in each participant using radiographic imaging.
Analysis Population Description: All randomized participants who received at least 1 dose of study drug and had baseline and a post-baseline measurement for change in tumor size.

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline, end of Cycle 2

| End point values | Phase 2: 300 mg Galunisertib + Gemcitabine | Phase 2: Placebo + Gemcitabine | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 104 | 52 | | |
| Units: Percent change in tumor size | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Independent Assessor 1 | 0.95 (0.90 to 1.01) | 0.92 (0.87 to 0.98) | | |
| Independent Assessor 2 | 1.03 (0.95 to 1.11) | 0.98 (0.92 to 1.05) | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate[ORR]) as Assessed by Independent Central Reviewers

| End point title | Phase 2: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate[ORR]) as Assessed by Independent Central Reviewers |
|---|---|

End point description:

Overall response rate is the best response of complete response (CR) or partial response (PR) as classified by the independent central review according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with at least 1 measurable lesion, multiplied by 100.
Analysis Population Description: All randomized participants who received at least 1 dose of study drug and had baseline and a post-baseline measurement for ORR.

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline to measured progressive disease (up to 2 years)

| **End point values** | Phase 2: 300 mg Galunisertib + Gemcitabine | Phase 2: Placebo + Gemcitabine | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 104 | 52 | | |
| Units: Percentage of Participants | | | | |
| number (confidence interval 95%) | 10.6 (5.4 to 18.1) | 3.8 (0.5 to 13.2) | | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2: Population Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Time Zero to 24 Hours (AUC[0-24])

| End point title | Phase 2: Population Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Time Zero to 24 Hours (AUC[0-24]) |
|---|---|

End point description:

Analysis Population Description: Phase 2: All randomized participants who received at least 1 dose of study drug with evaluable PK data.

| End point type | Secondary |
|---|---|

End point timeframe:

Cycle 1 Days 1 and 14, (predose; 0.5 to 2 hours, 3.5 to 5 hours post dose); Cycle 1 Day 7 (predose; 0.5 to 2 hours postdose); Cycle 1 Day 15, morning; Cycle 1 Day 16, morning

| End point values | Phase 2: 300 mg Galunisertib + Gemcitabine | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 99 | | | |
| Units: mg*h/L | | | | |
| arithmetic mean (inter-quartile range (Q1-Q3)) | 5.56 (3.82 to 7.91) | | | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2: Population PK: Maximum Concentration (Cmax) of galunisertib

| End point title | Phase 2: Population PK: Maximum Concentration (Cmax) of galunisertib |
|---|---|

End point description:

Analysis Population Description: Phase 2: All randomized participants who received at least 1 dose of study drug with evaluable PK data.

| End point type | Secondary |
|---|---|

End point timeframe:

Cycle 1 Days 1 and 14, (predose; 0.5 to 2 hours, 3.5 to 5 hours post dose); Cycle 1 Day 7 (predose; 0.5 to 2 hours postdose); Cycle 1 Day 15, morning; Cycle 1 Day 16, morning

| End point values | Phase 2: 300 mg Galunisertib + Gemcitabine | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 99 | | | |
| Units: ng/mL | | | | |
| arithmetic mean (inter-quartile range (Q1-Q3)) | 904 (668 to 1194) | | | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Phase 2: Change from baseline in Brief Pain Inventory-short form (BPI-sf) at study completion

| End point title | Phase 2: Change from baseline in Brief Pain Inventory-short form (BPI-sf) at study completion |
|---|---|

End point description:

The BPI-SF Pain Severity Subscale was a participant-rated questionnaire that measured the severity of pain. Severity scores could have ranged from 0 (no pain) to 10 (pain as bad as you can imagine) for questions assessing worst pain, least pain, and average pain in the past 24 hours, and pain right now. The BPI-SF Interference Subscale measured the interference of pain with the participant's ability to function. Interference scores could have ranged from 0 (does not interfere) to 10 (completely interferes)

for questions assessing interference of pain in the past 24 hours for general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life.
Analysis Population Description: All randomized participants who received at least 1 dose of study drug and had baseline and a post-baseline measurement for BPI-sf.

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline, study treatment completion (up to 1 year)

| **End point values** | Phase 2: 300 mg Galunisertib + Gemcitabine | Phase 2: Placebo + Gemcitabine | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 7 | 2 | | |
| Units: Units on a scale | | | | |
| arithmetic mean (standard deviation) | 2.54 (± 2.53) | 1.50 (± 2.12) | | |

**Statistical analyses**

No statistical analyses for this end point

## Secondary: Phase 2: Change from baseline in carbohydrate antigen 19.9 (CA19-9) level at first study completion follow-up

| End point title | Phase 2: Change from baseline in carbohydrate antigen 19.9 (CA19-9) level at first study completion follow-up |
|---|---|

End point description:

Carbohydrate antigen 19-9 (CA 19-9) is a modified Lewis(a) blood group antigen, and has been used as a tumor marker. The outcome measure is the median, minimum and maximum values from participants who had samples collected at baseline and at follow-up.
Analysis Population Description: All randomized participants who received at least 1 dose of study drug and had baseline and a post-baseline measurement for CA19-9 level.

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline, study treatment completion after first follow up visit (up to 1 year)

| **End point values** | Phase 2: 300 mg Galunisertib + Gemcitabine | Phase 2: Placebo + Gemcitabine | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 38 | 21 | | |
| Units: Units/Milliliter | | | | |
| median (full range (min-max)) | 32.7 (-93.8 to 3636.3) | -33.3 (-98.1 to 2460.9) | | |

## Statistical analyses

No statistical analyses for this end point

## Adverse events

| Adverse events information | |
|---|---|
| Timeframe for reporting adverse events: | |
| Up to 30 days | |
| Adverse event reporting additional description: | |
| All participants who received at least one dose of study drug. | |
| Assessment type | Systematic |

| Dictionary used | |
|---|---|
| Dictionary name | MedDRA |
| Dictionary version | 18.1 |

| Reporting groups | |
|---|---|
| Reporting group title | Phase 1b: 80 mg LY2157299 + Gemcitabine |
| Reporting group description: - | |
| Reporting group title | Phase 1b: 160 mg LY2157299 + Gemcitabine |
| Reporting group description: - | |
| Reporting group title | Phase 1b: 300 mg LY2157299 + Gemcitabine |
| Reporting group description: - | |
| Reporting group title | Phase 2: 300 mg LY2157299 + Gemcitabine |
| Reporting group description: - | |
| Reporting group title | Phase 2: Placebo + Gemcitabine |
| Reporting group description: - | |

| Serious adverse events | Phase 1b: 80 mg LY2157299 + Gemcitabine | Phase 1b: 160 mg LY2157299 + Gemcitabine | Phase 1b: 300 mg LY2157299 + Gemcitabine |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 1 / 4 (25.00%) | 2 / 5 (40.00%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| malignant ascites | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tumour pain | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Vascular disorders | | | |
| orthostatic hypotension | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| shock haemorrhagic | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Surgical and medical procedures | | | |
| pancreatic pseudocyst drainage | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| asthenia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| fatigue | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| general physical health deterioration | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| multi-organ failure | | | |

| | | | |
|---|---|---|---|
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| oedema peripheral | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pain | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pyrexia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 1 / 5 (20.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| dyspnoea | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| haemothorax | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pleural effusion | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pneumonitis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pneumothorax | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pulmonary embolism | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pulmonary hypertension | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| respiratory distress | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| respiratory failure | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| Psychiatric disorders | | | |
| agitation | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| confusional state | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| delirium | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Device occlusion | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| blood bilirubin increased | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| blood creatinine increased | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |

| | | | |
|---|---|---|---|
| fall | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| femur fracture | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gastrointestinal stoma complication | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| humerus fracture | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| lower limb fracture | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| toxicity to various agents | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| angina pectoris | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cardiac failure | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cardiogenic shock | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| myocardial ischaemia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pericardial effusion | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| cerebral ischaemia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cerebrovascular accident | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| disturbance in attention | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hepatic encephalopathy | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| ischaemic stroke | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| presyncope | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| syncope | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| abdominal pain | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| abdominal pain upper | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| ascites | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| colitis ischaemic | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| constipation | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| diarrhoea | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| duodenal obstruction | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| duodenal stenosis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| femoral hernia incarcerated | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gastric ulcer | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gastrointestinal haemorrhage | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| haematemesis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| ileus paralytic | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| intestinal obstruction | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| large intestinal obstruction | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| lower gastrointestinal haemorrhage | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| melaena | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| nausea | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| obstruction gastric | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| oesophagitis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| pancreatitis acute | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| small intestinal obstruction | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| upper gastrointestinal haemorrhage | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| vomiting | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| bile duct obstruction | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bile duct stenosis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholangitis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholangitis acute | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholecystitis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholecystitis acute | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholestasis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hepatic cirrhosis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hepatic failure | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| hepatocellular injury | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| jaundice cholestatic | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| acute kidney injury | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| renal failure | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| ureteric stenosis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| osteoarthritis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| rhabdomyolysis | | | |

| | | | |
|---|---|---|---|
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 1 / 5 (20.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| biliary tract infection | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bronchitis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| catheter site infection | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholecystitis infective | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| device related infection | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| endocarditis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| infection | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| liver abscess | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| lung infection | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| peritonitis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| peritonitis bacterial | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pneumonia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|---|---|---|
| pyelonephritis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| sepsis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| staphylococcal infection | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| urinary tract infection | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| urosepsis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| diabetes mellitus | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hyperglycaemia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hyponatraemia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| **Serious adverse events** | Phase 2: 300 mg LY2157299 + Gemcitabine | Phase 2: Placebo + Gemcitabine | |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 56 / 103 (54.37%) | 26 / 52 (50.00%) | |
| number of deaths (all causes) | 7 | 5 | |
| number of deaths resulting from adverse events | 2 | 0 | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| malignant ascites | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| tumour pain | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular disorders | | | |
| orthostatic hypotension | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| shock haemorrhagic | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Surgical and medical procedures | | | |
| pancreatic pseudocyst drainage | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General disorders and administration site conditions | | | |
| asthenia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| fatigue | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| general physical health deterioration | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 2 / 103 (1.94%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| multi-organ failure | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| oedema peripheral | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| pain | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| pyrexia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 4 / 103 (3.88%) | 3 / 52 (5.77%) | |
| occurrences causally related to treatment / all | 1 / 4 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| dyspnoea | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 2 / 103 (1.94%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| haemothorax | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| pleural effusion | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| pneumonitis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| pneumothorax | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| pulmonary embolism | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 5 / 103 (4.85%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 1 / 5 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| pulmonary hypertension | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| respiratory distress | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| respiratory failure | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Psychiatric disorders | | | |
| agitation | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 103 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| confusional state | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| delirium | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Device occlusion | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 3 / 103 (2.91%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| **Investigations** | | | |
| blood bilirubin increased | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| blood creatinine increased | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| **Injury, poisoning and procedural complications** | | | |
| fall | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| femur fracture | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| gastrointestinal stoma complication | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| humerus fracture | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| lower limb fracture | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| toxicity to various agents | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 1 / 1 | 0 / 0 | |
| **Cardiac disorders** | | | |
| angina pectoris | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| cardiac failure | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| cardiogenic shock | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| myocardial ischaemia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| pericardial effusion | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 1 / 1 | 0 / 0 | |
| **Nervous system disorders** | | | |
| cerebral ischaemia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| cerebrovascular accident | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| disturbance in attention | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| hepatic encephalopathy | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| ischaemic stroke | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| presyncope | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| syncope | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| **Gastrointestinal disorders** | | | |
| abdominal pain | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 5 / 103 (4.85%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| abdominal pain upper | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| ascites | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| colitis ischaemic | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| constipation | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| diarrhoea | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| duodenal obstruction | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|---|---|---|
| duodenal stenosis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| femoral hernia incarcerated | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| gastric ulcer | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| gastrointestinal haemorrhage | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| haematemesis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| ileus paralytic | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| intestinal obstruction | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 103 (0.97%) | 3 / 52 (5.77%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| large intestinal obstruction | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| lower gastrointestinal haemorrhage | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| melaena | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| nausea | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 2 / 103 (1.94%) | 2 / 52 (3.85%) | |
| occurrences causally related to treatment / all | 2 / 2 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| obstruction gastric | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| oesophagitis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|---|---|---|
| pancreatitis acute | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| small intestinal obstruction | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 2 / 103 (1.94%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| upper gastrointestinal haemorrhage | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| vomiting | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 4 / 103 (3.88%) | 2 / 52 (3.85%) | |
| occurrences causally related to treatment / all | 1 / 4 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatobiliary disorders | | | |
| bile duct obstruction | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| bile duct stenosis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 2 / 103 (1.94%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| cholangitis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 4 / 103 (3.88%) | 2 / 52 (3.85%) | |
| occurrences causally related to treatment / all | 0 / 7 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| cholangitis acute | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| cholecystitis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| cholecystitis acute | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| cholestasis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| hepatic cirrhosis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| hepatic failure | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|---|---|---|
| hepatocellular injury | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| jaundice cholestatic | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 3 / 103 (2.91%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal and urinary disorders | | | |
| acute kidney injury | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| renal failure | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| ureteric stenosis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| osteoarthritis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| rhabdomyolysis | | | |

| | | | |
|---|---|---|---|
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| biliary tract infection | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| bronchitis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| catheter site infection | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| cholecystitis infective | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| device related infection | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| endocarditis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| infection | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| liver abscess | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| lung infection | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 2 / 103 (1.94%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 1 / 1 | 0 / 1 | |
| peritonitis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| peritonitis bacterial | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| pneumonia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|---|---|---|
| pyelonephritis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| sepsis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 2 / 103 (1.94%) | 2 / 52 (3.85%) | |
| occurrences causally related to treatment / all | 0 / 2 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| staphylococcal infection | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| urinary tract infection | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| urosepsis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metabolism and nutrition disorders | | | |
| diabetes mellitus | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| hyperglycaemia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 103 (0.00%) | 1 / 52 (1.92%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| hyponatraemia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 5 %

| **Non-serious adverse events** | Phase 1b: 80 mg LY2157299 + Gemcitabine | Phase 1b: 160 mg LY2157299 + Gemcitabine | Phase 1b: 300 mg LY2157299 + Gemcitabine |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 5 / 5 (100.00%) | 4 / 4 (100.00%) | 5 / 5 (100.00%) |
| General disorders and administration site conditions | | | |
| asthenia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 3 / 5 (60.00%) |
| occurrences (all) | 0 | 1 | 4 |
| chills | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| early satiety | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| face oedema | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| fatigue | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 5 (40.00%) | 2 / 4 (50.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 2 | 4 | 1 |
| localised oedema | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| mucosal inflammation | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 2 / 5 (40.00%) |
| occurrences (all) | 0 | 0 | 4 |
| oedema peripheral | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 2 / 4 (50.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 1 | 2 | 1 |
| pain | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| peripheral swelling | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| pyrexia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 3 / 4 (75.00%) | 2 / 5 (40.00%) |
| occurrences (all) | 3 | 8 | 4 |
| Reproductive system and breast disorders | | | |
| pelvic pain | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| cough | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| dyspnoea | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| epistaxis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| oropharyngeal pain | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Psychiatric disorders | | | |
| anxiety | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 2 / 4 (50.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| depression | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| insomnia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Investigations | | | |
| alanine aminotransferase increased | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 2 / 5 (40.00%) | 1 / 4 (25.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 2 | 1 | 1 |
| aspartate aminotransferase increased | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 5 (40.00%) | 1 / 4 (25.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 2 | 1 | 1 |
| blood alkaline phosphatase increased<br>alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 2 / 5 (40.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| blood bilirubin increased<br>alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 0 | 1 |
| blood calcium decreased<br>alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| blood sodium decreased<br>alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| brain natriuretic peptide increased<br>alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| c-reactive protein increased<br>alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| ejection fraction decreased<br>alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 0 | 1 |
| neutrophil count decreased<br>alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 0 | 2 |

| | | | |
|---|---|---|---|
| platelet count decreased | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 0 | 1 |
| white blood cell count decreased | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 0 | 2 |
| Injury, poisoning and procedural complications | | | |
| ligament sprain | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Cardiac disorders | | | |
| Angina pectoris | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| atrial fibrillation | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nervous system disorders | | | |
| dizziness | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 1 | 1 |
| dysgeusia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| headache | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 3 / 5 (60.00%) | 1 / 4 (25.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 3 | 1 | 1 |

| | | | |
|---|---|---|---|
| neurotoxicity | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| paraesthesia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| peripheral sensory neuropathy | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 3 / 5 (60.00%) | 3 / 4 (75.00%) | 3 / 5 (60.00%) |
| occurrences (all) | 3 | 3 | 4 |
| febrile neutropenia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| leukopenia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| neutropenia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 3 / 5 (60.00%) | 2 / 4 (50.00%) | 3 / 5 (60.00%) |
| occurrences (all) | 3 | 2 | 3 |
| thrombocytopenia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 4 / 5 (80.00%) | 1 / 4 (25.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 4 | 5 | 1 |
| Gastrointestinal disorders | | | |

| | | | |
|---|---|---|---|
| abdominal pain | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 2 / 5 (40.00%) | 1 / 4 (25.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| abdominal pain upper | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| ascites | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 8 | 0 |
| constipation | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 2 / 5 (40.00%) | 2 / 4 (50.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 2 | 3 | 1 |
| diarrhoea | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 2 / 5 (40.00%) | 2 / 4 (50.00%) | 2 / 5 (40.00%) |
| occurrences (all) | 2 | 2 | 2 |
| dry mouth | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| dyspepsia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| gastrooesophageal reflux disease | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| nausea | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 5 (40.00%) | 4 / 4 (100.00%) | 4 / 5 (80.00%) |
| occurrences (all) | 2 | 5 | 9 |
| rectal haemorrhage | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| vomiting | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 3 / 5 (60.00%) | 3 / 4 (75.00%) | 3 / 5 (60.00%) |
| occurrences (all) | 3 | 4 | 4 |
| Hepatobiliary disorders | | | |
| jaundice | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Skin and subcutaneous tissue disorders | | | |
| dry skin | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 0 | 1 |
| erythema | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 2 / 4 (50.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| night sweats | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| pruritus | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| rash | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 5 (0.00%) | 2 / 4 (50.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 2 | 1 |
| Renal and urinary disorders | | | |
| dysuria | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| haematuria | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 2 / 5 (40.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| pollakiuria | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| urinary incontinence | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| arthralgia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 5 | 0 |
| arthritis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| back pain | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 0 | 1 |
| bone pain | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Muscle spasms | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| musculoskeletal chest pain | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| myalgia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 2 / 5 (40.00%) |
| occurrences (all) | 0 | 1 | 2 |
| pain in extremity | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Infections and infestations | | | |
| folliculitis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| nasopharyngitis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| pneumonia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| urinary tract infection | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Metabolism and nutrition disorders | | | |
| decreased appetite | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 2 / 4 (50.00%) | 2 / 5 (40.00%) |
| occurrences (all) | 1 | 2 | 2 |
| Dehydration | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| hyperglycaemia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 2 / 5 (40.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| hypoalbuminaemia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 3 / 5 (60.00%) | 1 / 4 (25.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 3 | 1 | 1 |
| hypocalcaemia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 4 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 1 | 0 | 1 |
| hypokalaemia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 0 / 4 (0.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 0 | 1 |
| hypomagnesaemia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 4 (0.00%) | 0 / 5 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| hyponatraemia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 4 (25.00%) | 1 / 5 (20.00%) |
| occurrences (all) | 0 | 1 | 1 |

| **Non-serious adverse events** | Phase 2: 300 mg LY2157299 + Gemcitabine | Phase 2: Placebo + Gemcitabine | |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 100 / 103 (97.09%) | 49 / 52 (94.23%) | |
| General disorders and administration site conditions | | | |
| asthenia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 36 / 103 (34.95%) | 17 / 52 (32.69%) | |
| occurrences (all) | 72 | 30 | |
| chills | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 10 / 103 (9.71%) | 4 / 52 (7.69%) | |
| occurrences (all) | 12 | 6 | |
| early satiety | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 0 / 52 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| face oedema | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 0 / 52 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| fatigue | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 21 / 103 (20.39%) | 9 / 52 (17.31%) | |
| occurrences (all) | 28 | 14 | |
| localised oedema | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 0 / 52 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| mucosal inflammation | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 103 (0.97%) | 4 / 52 (7.69%) | |
| occurrences (all) | 1 | 4 | |
| oedema peripheral | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 23 / 103 (22.33%) | 12 / 52 (23.08%) | |
| occurrences (all) | 33 | 15 | |
| pain | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 2 / 52 (3.85%) | |
| occurrences (all) | 1 | 2 | |
| peripheral swelling | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 0 / 52 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| pyrexia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 38 / 103 (36.89%) | 11 / 52 (21.15%) | |
| occurrences (all) | 93 | 17 | |
| Reproductive system and breast disorders | | | |
| pelvic pain | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 1 / 52 (1.92%) | |
| occurrences (all) | 1 | 1 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| cough | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 7 / 103 (6.80%) | 2 / 52 (3.85%) | |
| occurrences (all) | 10 | 2 | |
| dyspnoea | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 6 / 103 (5.83%) | 4 / 52 (7.69%) | |
| occurrences (all) | 7 | 4 | |
| epistaxis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 103 (1.94%) | 0 / 52 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| oropharyngeal pain | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 0 / 52 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Psychiatric disorders | | | |
| anxiety | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 6 / 103 (5.83%) | 4 / 52 (7.69%) | |
| occurrences (all) | 6 | 4 | |
| depression | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 4 / 52 (7.69%) | |
| occurrences (all) | 1 | 4 | |
| insomnia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 6 / 103 (5.83%) | 3 / 52 (5.77%) | |
| occurrences (all) | 6 | 4 | |
| Investigations | | | |
| alanine aminotransferase increased | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 10 / 103 (9.71%) | 3 / 52 (5.77%) | |
| occurrences (all) | 14 | 6 | |
| aspartate aminotransferase increased | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 8 / 103 (7.77%) | 2 / 52 (3.85%) | |
| occurrences (all) | 14 | 4 | |
| blood alkaline phosphatase increased | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 3 / 103 (2.91%) | 1 / 52 (1.92%) | |
| occurrences (all) | 3 | 1 | |
| blood bilirubin increased | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 8 / 103 (7.77%) | 0 / 52 (0.00%) | |
| occurrences (all) | 8 | 0 | |
| blood calcium decreased | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 0 / 52 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| blood sodium decreased | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 0 / 52 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| brain natriuretic peptide increased | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 0 / 52 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| c-reactive protein increased | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 2 / 103 (1.94%) | 3 / 52 (5.77%) | |
| occurrences (all) | 2 | 4 | |
| ejection fraction decreased | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 0 / 52 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| neutrophil count decreased | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 11 / 103 (10.68%) | 5 / 52 (9.62%) | |
| occurrences (all) | 31 | 10 | |
| platelet count decreased | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 17 / 103 (16.50%) | 8 / 52 (15.38%) | |
| occurrences (all) | 38 | 14 | |
| white blood cell count decreased | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 9 / 103 (8.74%) | 3 / 52 (5.77%) | |
| occurrences (all) | 16 | 3 | |

| | | | |
|---|---|---|---|
| Injury, poisoning and procedural complications | | | |
| ligament sprain | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 0 / 52 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Cardiac disorders | | | |
| Angina pectoris | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 0 / 52 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| atrial fibrillation | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 3 / 52 (5.77%) | |
| occurrences (all) | 1 | 3 | |
| Nervous system disorders | | | |
| dizziness | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 6 / 103 (5.83%) | 4 / 52 (7.69%) | |
| occurrences (all) | 7 | 7 | |
| dysgeusia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 2 / 103 (1.94%) | 0 / 52 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| headache | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 6 / 103 (5.83%) | 6 / 52 (11.54%) | |
| occurrences (all) | 6 | 8 | |
| neurotoxicity | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 0 / 52 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| paraesthesia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 4 / 103 (3.88%) | 1 / 52 (1.92%) | |
| occurrences (all) | 4 | 1 | |

| | | | |
|---|---|---|---|
| peripheral sensory neuropathy | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 1 / 52 (1.92%) | |
| occurrences (all) | 1 | 1 | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 44 / 103 (42.72%) | 28 / 52 (53.85%) | |
| occurrences (all) | 95 | 35 | |
| febrile neutropenia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 0 / 52 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| leukopenia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 4 / 103 (3.88%) | 3 / 52 (5.77%) | |
| occurrences (all) | 6 | 8 | |
| neutropenia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 34 / 103 (33.01%) | 17 / 52 (32.69%) | |
| occurrences (all) | 76 | 42 | |
| thrombocytopenia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 29 / 103 (28.16%) | 13 / 52 (25.00%) | |
| occurrences (all) | 83 | 21 | |
| Gastrointestinal disorders | | | |
| abdominal pain | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 26 / 103 (25.24%) | 12 / 52 (23.08%) | |
| occurrences (all) | 38 | 16 | |
| abdominal pain upper | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 12 / 103 (11.65%) | 5 / 52 (9.62%) | |
| occurrences (all) | 16 | 6 | |
| ascites | | | |

| | | | |
|---|---|---|---|
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 13 / 103 (12.62%) | 1 / 52 (1.92%) | |
| occurrences (all) | 14 | 1 | |
| constipation | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 30 / 103 (29.13%) | 15 / 52 (28.85%) | |
| occurrences (all) | 31 | 22 | |
| diarrhoea | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 23 / 103 (22.33%) | 12 / 52 (23.08%) | |
| occurrences (all) | 56 | 26 | |
| dry mouth | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 3 / 103 (2.91%) | 1 / 52 (1.92%) | |
| occurrences (all) | 3 | 1 | |
| dyspepsia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 8 / 103 (7.77%) | 3 / 52 (5.77%) | |
| occurrences (all) | 8 | 5 | |
| gastrooesophageal reflux disease | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 2 / 103 (1.94%) | 5 / 52 (9.62%) | |
| occurrences (all) | 2 | 5 | |
| nausea | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 39 / 103 (37.86%) | 17 / 52 (32.69%) | |
| occurrences (all) | 69 | 30 | |
| rectal haemorrhage | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 0 / 52 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| vomiting | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 27 / 103 (26.21%) | 19 / 52 (36.54%) | |
| occurrences (all) | 57 | 26 | |
| Hepatobiliary disorders | | | |
| jaundice | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 3 / 103 (2.91%) | 1 / 52 (1.92%) | |
| occurrences (all) | 3 | 1 | |
| Skin and subcutaneous tissue disorders | | | |
| dry skin | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 5 / 103 (4.85%) | 2 / 52 (3.85%) | |
| occurrences (all) | 6 | 2 | |
| erythema | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 2 / 103 (1.94%) | 2 / 52 (3.85%) | |
| occurrences (all) | 2 | 2 | |
| night sweats | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 2 / 103 (1.94%) | 2 / 52 (3.85%) | |
| occurrences (all) | 2 | 6 | |
| pruritus | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 5 / 103 (4.85%) | 2 / 52 (3.85%) | |
| occurrences (all) | 6 | 2 | |
| rash | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 5 / 103 (4.85%) | 5 / 52 (9.62%) | |
| occurrences (all) | 7 | 9 | |
| Renal and urinary disorders | | | |
| dysuria | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 4 / 103 (3.88%) | 0 / 52 (0.00%) | |
| occurrences (all) | 4 | 0 | |
| haematuria | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 103 (1.94%) | 0 / 52 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| pollakiuria | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 1 / 52 (1.92%) | |
| occurrences (all) | 0 | 1 | |
| urinary incontinence | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 0 / 52 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| arthralgia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 5 / 103 (4.85%) | 0 / 52 (0.00%) | |
| occurrences (all) | 6 | 0 | |
| arthritis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 0 / 52 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| back pain | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 8 / 103 (7.77%) | 4 / 52 (7.69%) | |
| occurrences (all) | 9 | 4 | |
| bone pain | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 1 / 52 (1.92%) | |
| occurrences (all) | 0 | 1 | |
| Muscle spasms | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 2 / 52 (3.85%) | |
| occurrences (all) | 1 | 2 | |
| musculoskeletal chest pain | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 103 (0.00%) | 0 / 52 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| myalgia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 6 / 103 (5.83%) | 0 / 52 (0.00%) | |
| occurrences (all) | 7 | 0 | |
| pain in extremity | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 4 / 103 (3.88%) | 1 / 52 (1.92%) | |
| occurrences (all) | 6 | 2 | |
| Infections and infestations | | | |
| folliculitis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 0 / 103 (0.00%) | 0 / 52 (0.00%) | |
| occurrences (all) | 0 | 0 | |
| nasopharyngitis | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 7 / 103 (6.80%) | 1 / 52 (1.92%) | |
| occurrences (all) | 9 | 1 | |
| pneumonia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 4 / 52 (7.69%) | |
| occurrences (all) | 1 | 4 | |
| urinary tract infection | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 6 / 103 (5.83%) | 3 / 52 (5.77%) | |
| occurrences (all) | 8 | 4 | |
| Metabolism and nutrition disorders | | | |
| decreased appetite | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 30 / 103 (29.13%) | 13 / 52 (25.00%) | |
| occurrences (all) | 42 | 18 | |
| Dehydration | | | |
| alternative dictionary used: MedDRA 18.1 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 103 (0.97%) | 3 / 52 (5.77%) | |
| occurrences (all) | 2 | 3 | |
| hyperglycaemia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 8 / 103 (7.77%) | 4 / 52 (7.69%) | |
| occurrences (all) | 14 | 5 | |
| hypoalbuminaemia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 4 / 103 (3.88%) | 1 / 52 (1.92%) | |
| occurrences (all) | 4 | 1 | |
| hypocalcaemia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 6 / 103 (5.83%) | 2 / 52 (3.85%) | |
| occurrences (all) | 7 | 2 | |
| hypokalaemia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 13 / 103 (12.62%) | 2 / 52 (3.85%) | |
| occurrences (all) | 17 | 2 | |
| hypomagnesaemia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 1 / 103 (0.97%) | 2 / 52 (3.85%) | |
| occurrences (all) | 1 | 2 | |
| hyponatraemia | | | |
| alternative dictionary used: MedDRA 18.1 | | | |
| subjects affected / exposed | 3 / 103 (2.91%) | 2 / 52 (3.85%) | |
| occurrences (all) | 3 | 2 | |

## More information

## Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|---|---|
| 01 March 2013 | After completing the Phase1b part of this study and based on additional safety and PD information from other studies with LY2157299 (see 2012 LY2157299 IB), the study was amended for the following reasons:<br><br>No Pharmaco Dynamic (PD) changes in gene expression profiles of peripheral blood mononuclear cell (PBMCs)/whole blood in patients treated with LY2157299 were seen, and therefore, there is no longer a requirement for collection of additional blood samples. All such PD assessments and their collection will be stopped, and no evaluation will be performed on all patients.<br><br>Protocol clarifications added per suggestions from sites and investigators, including clarification on bilirubin levels, the type of chest CT scans recommended for this study, the range of allowable chemotherapies during the adjuvant treatment. |
| 18 December 2015 | Amendment (c): This study was amended to enable all patients who are still in the study (either on study treatment, in short-term follow-up period or in long-term follow-up period) to be followed for overall survival after the study is considered complete for the primary objective. Minor editorial changes were made but not listed. |

Notes:

## Interruptions (globally)

Were there any global interruptions to the trial? No

## Limitations and caveats

None reported